IgG-switched CLL has a distinct immunogenetic signature from the common MD variant: ontogenetic implications
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
24240110
DOI
10.1158/1078-0432.ccr-13-1993
PII: 1078-0432.CCR-13-1993
Knihovny.cz E-resources
- MeSH
- Leukemia, Lymphocytic, Chronic, B-Cell genetics immunology MeSH
- Adult MeSH
- Gene Rearrangement, B-Lymphocyte MeSH
- Immunogenetics MeSH
- Immunoglobulin D genetics MeSH
- Immunoglobulin G genetics MeSH
- Immunoglobulin M genetics MeSH
- Middle Aged MeSH
- Humans MeSH
- Receptors, Antigen, B-Cell classification genetics MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Somatic Hypermutation, Immunoglobulin MeSH
- Immunoglobulin Heavy Chains genetics MeSH
- Immunoglobulin Variable Region genetics MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Immunoglobulin D MeSH
- Immunoglobulin G MeSH
- Immunoglobulin M MeSH
- Receptors, Antigen, B-Cell MeSH
- Immunoglobulin Heavy Chains MeSH
- Immunoglobulin Variable Region MeSH
PURPOSE: Immunoglobulin G-switched chronic lymphocytic leukemia (G-CLL) is a rare variant of CLL, whose origin and ontogenetic relationship to the common IgM/IgD (MD-CLL) variant remains undefined. Here, we sought for clues about the ontogeny of G-CLL versus MD-CLL by profiling the relevant IG gene repertoires. EXPERIMENTAL DESIGN: Using purpose-built bioinformatics methods, we performed detailed immunogenetic profiling of a multinational CLL cohort comprising 1,256 cases, of which 1,087 and 169 expressed IG mu/delta and gamma heavy chains, respectively. RESULTS: G-CLL has a highly skewed IG gene repertoire that is distinct from MD-CLL, especially in terms of (i) overuse of the IGHV4-34 and IGHV4-39 genes and (ii) differential somatic hypermutation (SHM) load. Repertoire differences were also found when comparing subgroups with similar SHM status and were mainly attributed to the exclusive representation in G-CLL of two major subsets with quasi-identical (stereotyped) B-cell receptors. These subsets, namely #4 (IGHV4-34/IGKV2-30) and #8 (IGHV4-39/IGKV1(D)-39), were found to display sharply contrasting SHM and clinical behavior. CONCLUSIONS: G-CLL exhibits an overall distinct immunogenetic signature from MD-CLL, prompting speculations about distinct ontogenetic derivation and/or immune triggering. The reasons underlying the differential regulation of SHM among G-CLL cases remain to be elucidated.
References provided by Crossref.org